Pseudovirus News and Research

RSS

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.

17 Jan 2022

Hollow fiber membranes efficiently remove synthetic SARS-CoV-2 from the air

Researchers re-design HFM filters for removing/deactivating viral aerosols.

13 Jan 2022

Cannabinoids may prevent infection with SARS-CoV-2, including variants

A new study published in the Journal of Natural Products of the American Chemical Society and American Society of Pharmacognosy has shown that isolated cannabinoids or those in hemp extracts have the potential to prevent and treat the infection with the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – primarily by blocking viral cell entry.

13 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Researchers screened BNT162b2 COVID-19 vaccine recipients and cloned broadly neutralizing antibodies from an elite vaccinee.

10 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron.

7 Jan 2022

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Researchers investigate SARS-CoV-2 antigenic drift by evaluating the neutralizing activity of sera from patients infected with all five SARS-CoV-2 VOCs.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

The purpose of this study was to determine the breadth of neutralizing activity generated by exposure to certain SARS-CoV-2 variants, vaccinations, or both.

6 Jan 2022

COVID boosters hinder SARS-CoV-2 Omicron

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol.

6 Jan 2022

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations.

5 Jan 2022

Exploring SARS-CoV-2-like viruses to mitigate the risk of zoonotic transmission to humans

In a new study, a team of researchers developed a genetic assay to evaluate several clade 2 and clade 3 receptor-binding domains (RBD) of spike (S) protein sequences of genus sarbecovirus.

5 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections.

4 Jan 2022

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research.

4 Jan 2022

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Pseudovirus News and Research

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

Hollow fiber membranes efficiently remove synthetic SARS-CoV-2 from the air

Cannabinoids may prevent infection with SARS-CoV-2, including variants

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

Isolated antibodies from BNT162b2 vacinee effective against Omicron variant

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Small molecule identified as a SARS-CoV-2 inhibitor

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

COVID boosters hinder SARS-CoV-2 Omicron

Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity

Exploring SARS-CoV-2-like viruses to mitigate the risk of zoonotic transmission to humans

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Time since COVID vaccination is a key driver of breakthrough Omicron infections

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News